Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin to reduce PAC/PVC after CABG
IRCT20250302064896N4Phase 3Completed
- Sponsor
- Ahvaz Jundishapur University of Medical Sciences
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of empagliflozin in coronary arteriosclerosis, atrial extrasystole (AES) and Premature ventricular complexes (PVC), sponsored by Ahvaz Jundishapur University of Medical Sciences. Primary endpoints: Incidence of premature atrial contractions (PAC) and Incidence of premature ventricular contractions (PVC). Started Sep 2025; status: completed.
02
Drugs
empagliflozin
03
Conditions
coronary arteriosclerosisatrial extrasystole (AES)Premature ventricular complexes (PVC)
Beyond the preview
Go deeper on IRCT20250302064896N4.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20250302064896N4.